Table 1

Characteristics and treatment schedules of the 107 patients with SpA treated with infliximab. This group of 107 patients comprised three different cohorts with slightly different retreatment schedules

Cohort 1Cohort 2Cohort 3Total
Number of patients314036107
Sex (M/F)24/728/1221/1573/34
Age (median and range)43 (26–73)47 (26–66)46 (28–72)46 (26–73)
Ankylosing spondylitis16192661
Psoriatic arthritis1118332
Undifferentiated spondyloarthropathy43714
Concomitant DMARD treatment101819
Concomitant corticosteroids2248
Induction scheme of infliximab5 mg/kg, weeks 0, 2, 65 mg/kg, weeks 0, 2, 65 mg/kg, weeks 0, 2, 65 mg/kg, weeks 0, 2, 6
First year infliximab re-treatment5 mg/kg every 14 weeks10 mg/kg every 14 weeks5 mg/kg every 8 weeks
Second year infliximab re-treatment5 mg/kg every 10 weeks5 mg/kg every 8 weeks
Third year infliximab re-treatment5 mg/kg every 8 weeks
Duration of follow up (patient years)83.163.644.8191.5